Lecanemab Receives Priority Review Status in Japan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/4/2026

1. PANW
2. SPY
3. ULTA
4. GTLB
5. USO
6. CRWD
7. MDT
8. GOOGL
9. VRTS
10. AVGO

Go back to Lecanemab Receives Priority Review Status in Japan
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 195.96 +7.13 (3.78%)
Previous Close $188.83    52 Week High $333.65 
Open $187.69    52 Week Low $223.02 
Day High $196.51    P/E 25.09 
Day Low $187.48    EPS $7.81 
Volume 891,787